Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phenomenex Chiral Screening Services Now Offered in China

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Collaboration with Chinese Academy of Sciences ensures fast, high-quality screening.

Phenomenex Inc. has announced the extension of its Chiral Screening Service to pharmaceutical and natural products customers in China.

The service is offered in collaboration with the Chinese Academy of Sciences (CAS), a leading academic and R&D center under which the Shanghai Institute of Organic Chemistry (SIOC) has developed a strong chiral team that works closely with Phenomenex.

The free Chiral Screening Service provides target screening using a library of HPLC columns including the Phenomenex Lux™ polysaccharide-based offerings, which demonstrate a success rate approaching 90 percent.

After resolving the chiral compound, Phenomenex delivers a method development and optimization plan to the customer within 10 business days - the same rapid turnaround the service promises in the U.S. and Europe.

“Our customer base in China has been growing rapidly and the expansion of our services will help us better serve them,” explains Michael Klein, brand manager for Phenomenex. “By teaming up with the CAS-SIOC, we are able to quickly roll out our rapid-response service.”

Enantiomers of chiral compounds may have different pharmacological effects in biological systems and they must be identified and evaluated separately.

“Resolving chiral compounds is relatively difficult, and column selection can be complicated,” continues Klein. “Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive’ our Lux columns.”

The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals.

Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phenomenex Launches Innovative, Industry-Focused Websites
Company builds on award-winning web presence with new digital experience.
Friday, February 22, 2013
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!